Update on denosumab treatment in postmenopausal women with osteoporosis. - Wikidata - awgldk - TriplyDB

Update on denosumab treatment in postmenopausal women with osteoporosis.

Update on denosumab treatment in postmenopausal women with osteoporosis.

http://www.wikidata.org/entity/Q35260850

about

Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.Conservative management of osteoporotic vertebral fractures: an update.Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

P2860

Q38616418-36CD0B0B-9671-4AEF-A671-0C6414A2C917 Q39057015-00D6E098-8674-4332-9464-1BD492987A16 Q39618928-B9E3B9BC-6564-48EE-8BE1-46C698D45E05

P2860

Update on denosumab treatment in postmenopausal women with osteoporosis.

http://www.wikidata.org/entity/Q35260850

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Update on denosumab treatment in postmenopausal women with osteoporosis.

@ast

Update on denosumab treatment in postmenopausal women with osteoporosis.

@en

type

label

Update on denosumab treatment in postmenopausal women with osteoporosis.

@ast

Update on denosumab treatment in postmenopausal women with osteoporosis.

@en

prefLabel

Update on denosumab treatment in postmenopausal women with osteoporosis.

@ast

Update on denosumab treatment in postmenopausal women with osteoporosis.

@en

P1433

Q35260850-EBAE36C4-2FDE-4098-BC3A-B65F10901C59

P1476

Q35260850-021DBF0C-759C-4C3B-8A44-A839D3B8F129

P2093

Q35260850-220AABB0-8BAF-4BFE-828F-CF39DEE8F4BA

P2860

Q35260850-2E628213-D508-4E94-BF59-838EAC14351D

Q35260850-64C4BDF0-A36B-45D4-8C92-392E29C88B2F

Q35260850-66306F0D-4C76-415B-9E98-AF217998FD5E

Q35260850-72EA83AC-2DD5-4C2E-8EF4-A1FDB52504D1

Q35260850-7701B90F-FDB2-4CD8-9E82-1DC84C4858A5

Q35260850-7FE1FD54-EBDD-44F5-AB3C-684C97FBAF4A

Q35260850-8C7A2FFC-1ADF-48C8-9090-6874B58D609E

Q35260850-8D4E7C34-4214-4381-AB9A-81C104B7ADEA

Q35260850-92FF7959-8D29-4C1B-A224-D0CD90BC32BB

Q35260850-95996E1D-B69D-4C52-B717-25E1DBAA2CCD

P304

Q35260850-CC9FEA87-4EF8-42ED-94C7-626A3A5E3560

P31

Q35260850-3751B3B7-EA6D-4B02-B3CC-DC2C1A2120D0

P356

Q35260850-711AAD27-B387-490C-BB92-82247C9BC34A

P433

Q35260850-39B7FE37-CB41-49D5-B6E9-1BFE7BD45222

P478

Q35260850-96E5E30A-E411-40A7-8FDA-0BFD4B3BAB17

P577

Q35260850-F009098D-F902-4EB9-ACEB-7B8B736F3B78

P5875

Q35260850-3FDE0683-98CD-4AF9-B8AA-84E3DD8ADE88

P698

Q35260850-41D2E4B5-7FA5-4506-A28A-008441C41F48

P921

Q35260850-78796734-9824-4226-94E5-67CAF8E537AA

P932

Q35260850-D0EB7C5B-A6DB-4F03-A94A-B9B671FB73E7

P356

ENM.2015.30.1.19

P1433

Endocrinology and metabolism : EnM

P1476

Update on denosumab treatment in postmenopausal women with osteoporosis.

@en

P2093

Yong Ki Min

http://www.w3.org/2001/XMLSchema#string

P2860

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Denosumab in postmenopausal women with low bone mineral density

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

Percentage of the population at high risk of osteoporotic fracture in South Korea: analysis of the 2010 Fifth Korean National Health and Nutrition Examination survey data.

Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension.

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial

RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.

Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.

P304

19-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3803/ENM.2015.30.1.19

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274399583

http://www.w3.org/2001/XMLSchema#string

P698

25827453

http://www.w3.org/2001/XMLSchema#string

P921

P932

4384669

http://www.w3.org/2001/XMLSchema#string